Related to FDA Grants New Approval for Rituxan in CD20-Positive CLL

• ChemGenex Needs to Develop Molecular Diagnostic to Gain FDA Approval for CML Drug
  
• FDA Green-Lights Genentech’s Lucentis for Macular Edema following Retinal Vein Occlusion
  
• FDA Sets Priority Review Schedule for BMS and Otsuka’s sNDA for Sprycel as First-Line CML Therapy
  
• FDA Panel Says Nay to Full Approval of Avastin in Her2-Negative Breast Cancer
  
• Genentech Receives Refuse to File Letter for T-DM1 in Metastatic Breast Cancer
  
• FDA Clears Herceptin-Chemotherapy Combo for Metastatic Her2+ Gastric Cancer
  
• Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent Future Squabbles
  
• FDA Clears Rituxan as Maintenance Therapy for Advanced Follicular Lymphoma
  
• After Panel’s Vote, Fate of Avastin for MBC in U.S. Rests with FDA Commissioner
  
• Genentech Takes Another Shot at Convincing FDA to Maintain Avastin’s Metastatic Breast Cancer Approval
  
• FDA Sanctions Abbott's Genetic FISH Panel for Leukemia Prognosis
  
• FDA Revokes Avastin Indication for Treatment of Metastatic Breast Cancer
  
• FDA Approves Tysabri Label Change and Test for JC Virus Infection in MS Patients
  
• FDA Approves Novartis' Flucelvax
  
• Roche's Genentech Wins FDA OK for Breast Cancer Drug
  
• Biogen Idec Prepares to Launch 4th MS Drug
  
• Roche's Antibody Approved as Front-Line Leukemia Treatment in Europe
  
• FDA Denies Use of Rituxan in Early Rheumatoid Arthritis
  
• FDA Green-Lights Novartis’ Tasigna as First-Line Therapy for Newly Diagnosed Ph+ CML
  
• Genmab and GSK Achieve Accelerated FDA Clearance of CLL Drug